Form 8-K · Current Report · Filed 2026-07-30
Guardant Health Reports Strong Q2 2026 Results and Raises Revenue Guidance
Guardant Health, Inc. reported a 44% increase in second-quarter 2026 revenue to $335.0 million, driven by strong performance in Oncology and Screening. The company raised its 2026 revenue guidance to $1.34 to $1.36 billion, representing growth of 36% to 38%. Oncology revenue grew 38% to $219.1 million, while Screening revenue surged over 250% to $52.9 million. Non-GAAP gross margin was 67% for the quarter. The company also highlighted recent FDA approvals and coverage decisions for its Shield blood test.
- Filer
- Guardant Health Inc. GH · NASDAQ
- Filed
- Accession
- 0001576280-26-000036
- CIK
- 0001576280
- Signal
- High impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Reported Item
Market reaction
Close before filing
$144.07
Next session
+12.4%
Since filing
+12.4%
Latest close
$161.99
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from GH reporting the same item, with the next session's move:
Insider tape
Within 45 days of this filing, GH insiders reported 130 Form 4 transactions — net selling of $48.8M.
About Guardant Health Inc.
Guardant Health Inc. is an innovative biotechnology company specializing in the development and commercialization of precision oncology diagnostics. This company is recognized for its groundbreaking work in non-invasive cancer detection through liquid biopsy technologies, which involve analyzing circulating tumor DNA in blood samples. Guardant Health’s primary function is to provide oncologists and researchers with critical tools and data to better understand cancer, tailor treatments, and monitor disease progression, potentially improving patient outcomes significantly. Guardant Health operates prominently in the healthcare and biotechnology sector, significantly impacting fields such as cancer research and personalized medicine. Their products and services are vital for facilitating early detection of cancer, identifying treatment options, and offering companion diagnostics for pharmaceutical developments. In the financial market, Guardant Health represents an important player within the precision medicine landscape, influencing investment within the biotechnology and healthcare sectors. Founded in 2012 and headquartered in Redwood City, California, the company continues to expand its portfolio and advance its technologies, playing a pivotal role in the fight against cancer at a global level.
Never miss another GH filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.